Collegium Pharmaceutical Inc (COLL)

Working capital turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	631,449	599,245	576,653	566,923	566,767	546,642	536,946	524,949	463,933	361,675	313,505	272,898	276,868	325,777	326,110	321,226	310,016	307,948	301,714	298,696
Total current assets	US$ in thousands	426,863	443,810	510,198	539,260	537,600	537,086	537,297	498,300	419,989	405,216	409,774	363,638	315,543	363,238	318,532	296,311	277,888	262,132	250,813	223,675
Total current liabilities	US$ in thousands	10,000	459,426	461,717	446,436	457,915	464,612	435,058	412,702	270,114	414,497	415,094	373,573	230,399	268,973	226,843	230,168	191,226	242,437	252,111	244,374
Working capital turnover		1.51	—	11.89	6.11	7.11	7.54	5.25	6.13	3.10	—	—	—	3.25	3.46	3.56	4.86	3.58	15.64	—	—

December 31, 2024 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $631,449K ÷ ($426,863K – $10,000K)
= 1.51

Collegium Pharmaceutical Inc's working capital turnover has shown fluctuations over the reported periods. The working capital turnover ratio is calculated by dividing net sales by the average working capital, where a higher ratio indicates efficient utilization of working capital to generate sales revenue.

The company reported a working capital turnover of 15.64 for September 30, 2020, indicating efficient management of working capital during that period. However, this ratio dropped significantly to 3.58 for December 31, 2020, suggesting a decrease in the efficiency of working capital utilization.

Subsequently, the ratios continued to fluctuate over the following periods, with values ranging from 3.25 to 7.54. Notably, the ratio improved in the most recent period, reaching 11.89 for June 30, 2024, which may indicate a more effective use of working capital to generate sales.

It is essential for Collegium Pharmaceutical Inc to closely monitor and manage its working capital turnover to ensure optimal efficiency in utilizing its working capital resources to drive sales and overall business performance.